deltatrials
Recruiting PHASE3 INTERVENTIONAL 3-arm NCT06834100

Assessment of Immunogenicity, Reactogenicity and Safety of the Drug GNG-DE in Comparison With the Reference Drug

Simple Blinded Multicenter Randomized Comparative Study to Assess Immunogenicity, Reactogenicity and Safety of the Drug GNG-DE

Sponsor: NPO Petrovax

Conditions Infections Meningococcal
Interventions polysaccharide conjugated vaccine for prevention of meningococcal infection of serogroups A, C, W, Y
Updated 4 times since 2025 Last updated: Dec 24, 2025 Started: Feb 12, 2025 Primary completion: Dec 31, 2025 Completion: Dec 31, 2025
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Infections and Meningococcal, this trial is actively recruiting participants. The trial is conducted by NPO Petrovax and has accumulated 4 data snapshots since 2025. Infectious disease trials contribute critical data for public health response and treatment development.

Status Flow

~Mar 2025 – ~Aug 2025 · 5 months · monthly snapshotNot Yet Recruiting~Aug 2025 – ~Sep 2025 · 31 days · monthly snapshot~Sep 2025 – ~Jan 2026 · 4 months · monthly snapshotRecruiting~Jan 2026 – present · 8 months · monthly snapshotRecruiting

Change History

4 versions recorded

  1. Jan 2026 — Present [monthly]

    Recruiting PHASE3

  2. Sep 2025 — Jan 2026 [monthly]

    Recruiting PHASE3

  3. Aug 2025 — Sep 2025 [monthly]

    Recruiting PHASE3

    Status: Not Yet Recruiting → Recruiting

  4. Mar 2025 — Aug 2025 [monthly]

    Not Yet Recruiting PHASE3

    First recorded

Feb 2025

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • NPO Petrovax
Data source: NPO Petrovax

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations